ArticleERJ open research2026

Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network.

Merete B Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.